Physician profile
Maggi C Ormand
NPI 1497022305
$11,164.66
in general payments reported to CMS, 2019-2025
47 companies · $2,948 in 2025
The $2,948 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.39 · 2022: $2,625 · 2023: $3,101 · 2024: $2,479 · 2025: $2,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,528.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,038.69 | 2022-2025 | |
| Pfizer INC. | $938.56 | 2023-2025 | |
| Lilly USA, LLC | $901.76 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $709.90 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $627.25 | 2022-2025 | Breztri, Farxiga, Nexium |
| Abbott Laboratories | $532.30 | 2022-2025 | Freestyle Libre 3, Octrode, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487.98 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $384.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $315.12 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $305.76 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $296.71 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $294.31 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.04 | 2022-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Preventric Diagnostics, INC. | $232.17 | 2022 | |
| Dexcom, INC. | $224.98 | 2022-2024 | Dexcom G6 Transmitter |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $224.68 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $208.82 | 2022-2024 | Verquvo, Belsomra, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $207.10 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $167.89 | 2023-2025 | Auvelity, Symbravo |
| Daiichi Sankyo INC. | $163.44 | 2022-2024 | Injectafer |
| Corcept Therapeutics | $145.46 | 2024-2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $137.42 | 2025 | Rexulti |
| Lundbeck LLC | $135.47 | 2023-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $129.79 | 2022 | |
| Exact Sciences Corporation | $125.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $121.63 | 2023-2025 | Veozah, Myrbetriq |
| Corium, LLC | $116.80 | 2025 | Azstarys |
| Radius Health, INC. | $82.77 | 2023-2025 | Tymlos |
| Amgen INC. | $80.63 | 2023-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $63.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $58.81 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $57.63 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $53.81 | 2022-2025 | Trintellix |
| Si-Bone, INC. | $46.38 | 2024 | |
| Paratek Pharmaceuticals, INC. | $45.65 | 2025 | Nuzyra, Xhance |
| Globus Medical, INC. | $42.30 | 2025 | Senza |
| Sanofi Pasteur INC. | $31.50 | 2025 | |
| Eisai INC. | $25.93 | 2022 | |
| Ascensia Diabetes Care US INC. | $23.82 | 2025 | |
| Inari Medical, INC. | $22.60 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $21.12 | 2025 | Opsumit, Uptravi |
| Siemens Medical Solutions USA, INC. | $17.49 | 2025 | Immulite 1000 Immunoassay System |
| Mylan Specialty L.P. | $16.83 | 2022 | |
| Esperion Therapeutics, INC. | $16.57 | 2022 | |
| Viatris Specialty LLC | $14.80 | 2025 | Yupelri |
| Azurity Pharmaceuticals, INC. | $14.25 | 2022 | |
| Antares Pharma, INC. | $13.52 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggi Ormand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.